Dynamics of expression of drug transporters: Methods for Appraisal

Marta Gromicho, J. Rueff, AS Rodrigues

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Cellular drug resistance remains a major concern in cancer therapy and usually results from increased expression of ABC drug transporters. Imatinib mesylate (IM), a competitive inhibitor of BCR/ABL1 tyrosine kinase activity, is the current standard therapy for chronic myeloid leukaemia (CML) which is caused by the BCR/ABL1 gene fusion encoding a constitutively active tyrosine kinase. However, up to 33 % of CML patients do not respond to therapy either initially or due to acquired resistance. Usually, IM resistance is due to the presence of BCR-ABL1 mutations but in many cases resistance is far from being completely understood or from being satisfactorily addressed from a therapeutic standpoint. Although second- and third-generation TKIs (e.g., dasatinib (DA), nilotinib, and bosutinib) were developed to override this phenomenon, resistance remains an unsolved problem. Above all, as more patients are treated with TKIs, more cases of resistance are expected and the discovery of biomarkers of resistance acquires a crucial clinical significance. We established a valuable in vitro experimental system that mimics the acquired resistance in the absence of mutations. It was developed by the continuous exposure of K562, a human CML-derived cell line expressing BCR-ABL gene, to increasing concentrations of IM and DA (over 36 and 24 weeks, respectively) allowing us to obtain several cell lines with different resistance levels, and therefore to evaluate drug transporters’ role in the dynamic cellular responses allied with resistance evolution. The development of such cell models is fundamental to understand the role of drug transporters in resistance since the majority of previous studies were performed on cell lines engineered to over-express a single transporter. Drug transporters were overexpressed in the majority of resistant cell lines and cell lines from all levels of resistance had increased expression of more than one drug transporter. However, the transporters that attain higher mRNA overexpression (e.g., ABCB1 and ABCG2) did not substantiate a linear relation with the level of resistance. Also, variation in expression of these genes occurs over time of exposure to the same concentration of IM while maintaining resistance, suggesting that resistance mechanisms could vary dynamically in patients as disease progresses. Indeed, we observed that while responding patients demonstrated stable transporters’ expression signatures in consecutive samples, in IM-resistant patients they vary significantly over time, advising caution when comparing single-point samples from responsive and resistant patients.

Original languageEnglish
Title of host publicationMethods in Molecular Biology
PublisherHumana Press Inc
Pages75-85
Number of pages11
Volume1395
DOIs
Publication statusPublished - 2016

Publication series

NameMethods in Molecular Biology
Volume1395
ISSN (Print)10643745

Fingerprint

Cell Line
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Pharmaceutical Preparations
Protein-Tyrosine Kinases
Mutation
ATP-Binding Cassette Transporters
Gene Fusion
Therapeutics
Drug Resistance
Biomarkers
Imatinib Mesylate
Gene Expression
Messenger RNA
Genes
Neoplasms
Dasatinib

Keywords

  • Chronic myeloid leukemia
  • Drug transporters
  • Gene expression
  • K562 cell line
  • Multidrug resistance

Cite this

Gromicho, M., Rueff, J., & Rodrigues, AS. (2016). Dynamics of expression of drug transporters: Methods for Appraisal. In Methods in Molecular Biology (Vol. 1395, pp. 75-85). (Methods in Molecular Biology; Vol. 1395). Humana Press Inc. https://doi.org/10.1007/978-1-4939-3347-1_6
Gromicho, Marta ; Rueff, J. ; Rodrigues, AS. / Dynamics of expression of drug transporters : Methods for Appraisal. Methods in Molecular Biology. Vol. 1395 Humana Press Inc, 2016. pp. 75-85 (Methods in Molecular Biology).
@inbook{4e759e0acfc543c69854f9abdd303db3,
title = "Dynamics of expression of drug transporters: Methods for Appraisal",
abstract = "Cellular drug resistance remains a major concern in cancer therapy and usually results from increased expression of ABC drug transporters. Imatinib mesylate (IM), a competitive inhibitor of BCR/ABL1 tyrosine kinase activity, is the current standard therapy for chronic myeloid leukaemia (CML) which is caused by the BCR/ABL1 gene fusion encoding a constitutively active tyrosine kinase. However, up to 33 {\%} of CML patients do not respond to therapy either initially or due to acquired resistance. Usually, IM resistance is due to the presence of BCR-ABL1 mutations but in many cases resistance is far from being completely understood or from being satisfactorily addressed from a therapeutic standpoint. Although second- and third-generation TKIs (e.g., dasatinib (DA), nilotinib, and bosutinib) were developed to override this phenomenon, resistance remains an unsolved problem. Above all, as more patients are treated with TKIs, more cases of resistance are expected and the discovery of biomarkers of resistance acquires a crucial clinical significance. We established a valuable in vitro experimental system that mimics the acquired resistance in the absence of mutations. It was developed by the continuous exposure of K562, a human CML-derived cell line expressing BCR-ABL gene, to increasing concentrations of IM and DA (over 36 and 24 weeks, respectively) allowing us to obtain several cell lines with different resistance levels, and therefore to evaluate drug transporters’ role in the dynamic cellular responses allied with resistance evolution. The development of such cell models is fundamental to understand the role of drug transporters in resistance since the majority of previous studies were performed on cell lines engineered to over-express a single transporter. Drug transporters were overexpressed in the majority of resistant cell lines and cell lines from all levels of resistance had increased expression of more than one drug transporter. However, the transporters that attain higher mRNA overexpression (e.g., ABCB1 and ABCG2) did not substantiate a linear relation with the level of resistance. Also, variation in expression of these genes occurs over time of exposure to the same concentration of IM while maintaining resistance, suggesting that resistance mechanisms could vary dynamically in patients as disease progresses. Indeed, we observed that while responding patients demonstrated stable transporters’ expression signatures in consecutive samples, in IM-resistant patients they vary significantly over time, advising caution when comparing single-point samples from responsive and resistant patients.",
keywords = "Chronic myeloid leukemia, Drug transporters, Gene expression, K562 cell line, Multidrug resistance",
author = "Marta Gromicho and J. Rueff and AS Rodrigues",
year = "2016",
doi = "10.1007/978-1-4939-3347-1_6",
language = "English",
volume = "1395",
series = "Methods in Molecular Biology",
publisher = "Humana Press Inc",
pages = "75--85",
booktitle = "Methods in Molecular Biology",

}

Gromicho, M, Rueff, J & Rodrigues, AS 2016, Dynamics of expression of drug transporters: Methods for Appraisal. in Methods in Molecular Biology. vol. 1395, Methods in Molecular Biology, vol. 1395, Humana Press Inc, pp. 75-85. https://doi.org/10.1007/978-1-4939-3347-1_6

Dynamics of expression of drug transporters : Methods for Appraisal. / Gromicho, Marta; Rueff, J. ; Rodrigues, AS.

Methods in Molecular Biology. Vol. 1395 Humana Press Inc, 2016. p. 75-85 (Methods in Molecular Biology; Vol. 1395).

Research output: Chapter in Book/Report/Conference proceedingChapter

TY - CHAP

T1 - Dynamics of expression of drug transporters

T2 - Methods for Appraisal

AU - Gromicho, Marta

AU - Rueff, J.

AU - Rodrigues, AS

PY - 2016

Y1 - 2016

N2 - Cellular drug resistance remains a major concern in cancer therapy and usually results from increased expression of ABC drug transporters. Imatinib mesylate (IM), a competitive inhibitor of BCR/ABL1 tyrosine kinase activity, is the current standard therapy for chronic myeloid leukaemia (CML) which is caused by the BCR/ABL1 gene fusion encoding a constitutively active tyrosine kinase. However, up to 33 % of CML patients do not respond to therapy either initially or due to acquired resistance. Usually, IM resistance is due to the presence of BCR-ABL1 mutations but in many cases resistance is far from being completely understood or from being satisfactorily addressed from a therapeutic standpoint. Although second- and third-generation TKIs (e.g., dasatinib (DA), nilotinib, and bosutinib) were developed to override this phenomenon, resistance remains an unsolved problem. Above all, as more patients are treated with TKIs, more cases of resistance are expected and the discovery of biomarkers of resistance acquires a crucial clinical significance. We established a valuable in vitro experimental system that mimics the acquired resistance in the absence of mutations. It was developed by the continuous exposure of K562, a human CML-derived cell line expressing BCR-ABL gene, to increasing concentrations of IM and DA (over 36 and 24 weeks, respectively) allowing us to obtain several cell lines with different resistance levels, and therefore to evaluate drug transporters’ role in the dynamic cellular responses allied with resistance evolution. The development of such cell models is fundamental to understand the role of drug transporters in resistance since the majority of previous studies were performed on cell lines engineered to over-express a single transporter. Drug transporters were overexpressed in the majority of resistant cell lines and cell lines from all levels of resistance had increased expression of more than one drug transporter. However, the transporters that attain higher mRNA overexpression (e.g., ABCB1 and ABCG2) did not substantiate a linear relation with the level of resistance. Also, variation in expression of these genes occurs over time of exposure to the same concentration of IM while maintaining resistance, suggesting that resistance mechanisms could vary dynamically in patients as disease progresses. Indeed, we observed that while responding patients demonstrated stable transporters’ expression signatures in consecutive samples, in IM-resistant patients they vary significantly over time, advising caution when comparing single-point samples from responsive and resistant patients.

AB - Cellular drug resistance remains a major concern in cancer therapy and usually results from increased expression of ABC drug transporters. Imatinib mesylate (IM), a competitive inhibitor of BCR/ABL1 tyrosine kinase activity, is the current standard therapy for chronic myeloid leukaemia (CML) which is caused by the BCR/ABL1 gene fusion encoding a constitutively active tyrosine kinase. However, up to 33 % of CML patients do not respond to therapy either initially or due to acquired resistance. Usually, IM resistance is due to the presence of BCR-ABL1 mutations but in many cases resistance is far from being completely understood or from being satisfactorily addressed from a therapeutic standpoint. Although second- and third-generation TKIs (e.g., dasatinib (DA), nilotinib, and bosutinib) were developed to override this phenomenon, resistance remains an unsolved problem. Above all, as more patients are treated with TKIs, more cases of resistance are expected and the discovery of biomarkers of resistance acquires a crucial clinical significance. We established a valuable in vitro experimental system that mimics the acquired resistance in the absence of mutations. It was developed by the continuous exposure of K562, a human CML-derived cell line expressing BCR-ABL gene, to increasing concentrations of IM and DA (over 36 and 24 weeks, respectively) allowing us to obtain several cell lines with different resistance levels, and therefore to evaluate drug transporters’ role in the dynamic cellular responses allied with resistance evolution. The development of such cell models is fundamental to understand the role of drug transporters in resistance since the majority of previous studies were performed on cell lines engineered to over-express a single transporter. Drug transporters were overexpressed in the majority of resistant cell lines and cell lines from all levels of resistance had increased expression of more than one drug transporter. However, the transporters that attain higher mRNA overexpression (e.g., ABCB1 and ABCG2) did not substantiate a linear relation with the level of resistance. Also, variation in expression of these genes occurs over time of exposure to the same concentration of IM while maintaining resistance, suggesting that resistance mechanisms could vary dynamically in patients as disease progresses. Indeed, we observed that while responding patients demonstrated stable transporters’ expression signatures in consecutive samples, in IM-resistant patients they vary significantly over time, advising caution when comparing single-point samples from responsive and resistant patients.

KW - Chronic myeloid leukemia

KW - Drug transporters

KW - Gene expression

KW - K562 cell line

KW - Multidrug resistance

UR - http://www.scopus.com/inward/record.url?scp=84964490737&partnerID=8YFLogxK

U2 - 10.1007/978-1-4939-3347-1_6

DO - 10.1007/978-1-4939-3347-1_6

M3 - Chapter

VL - 1395

T3 - Methods in Molecular Biology

SP - 75

EP - 85

BT - Methods in Molecular Biology

PB - Humana Press Inc

ER -

Gromicho M, Rueff J, Rodrigues AS. Dynamics of expression of drug transporters: Methods for Appraisal. In Methods in Molecular Biology. Vol. 1395. Humana Press Inc. 2016. p. 75-85. (Methods in Molecular Biology). https://doi.org/10.1007/978-1-4939-3347-1_6